HUTCHMED (China) Limited (HCM)

Broker Ratings

⚠️ No article content returned.

Share on:
Find more news, interviews, share price & company profile here for:

    HUTCHMED showcases new oncology data at ASCO 2025

    HUTCHMED (China) Limited is set to unveil groundbreaking data on key cancer therapies at the 2025 ASCO Annual Meeting, highlighting promising advancements in NSCLC and solid tumors.

    HUTCHMED completes Savolitinib trial enrollment

    HUTCHMED has successfully completed patient enrollment for a Phase II trial of savolitinib, targeting gastric cancer patients with MET amplification.

      Search

      Search